We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Varian Halcyon System Gets 510(k) Approval from the FDA
Read MoreHide Full Article
Palo Alto, CA-based manufacturer of medical devices and software, Varian Medical Systems, Inc. recently announced the 510(k) approval for its Halcyon system. The Halcyon radiotherapy treatment system has been designed to offer cost-effective cancer care worldwide. In June Varian showcased the Halcyon system at the 2017 DEGRO meeting, the German radiation oncology society, in Berlin.
The Halcyon system streamlines every aspect of image-guided volumetric intensity modulated radiotherapy (IMRT). The system has received both 510(k) clearance and a CE mark from the European directive. Notably, Varian can initiate the selling process of the Halcyon system in the U.S. However, the system requires Eclipse 15.1.1 planning software, which is currently pending for a 510(k) approval.
Halcyon system has a user-friendly design and it automates, streamlines and simplifies almost every aspect of cancer treatment. Per management, the system offers treatment for prostate, breast, head & neck, and most other forms of cancer.
We note that the global radiotherapy market is expected to reach a worth of $7,544.8 million by 2020, at a CAGR of 6.2%. Taking the bountiful prospects in the global niche space into consideration, the latest development should boost investor confidence.
Price Movement
Varian has a Zacks Rank #2 (Buy).
The company has had an impressive run on the bourse over the last one month. Varian has gained almost 1.02%, higher than the Zacks classified Medical - Instruments sub-industry’s decline of 1.3%. Furthermore, the stock’s price level was higher than the S&P 500’s negative return of 0.6% over the same time frame.
Meanwhile, the company’s recent earnings estimates have been mixed at best. The current year has seen one analyst move north in the past two months, while next year estimates have seen two upward revisions, compared to no movement in the opposite direction.
This has had a significant impact on the consensus estimate, as the current quarter estimates lost roughly 1% over the last two months, while next year estimates increased 0.9%.
Inogen has a long-term expected earnings growth rate of 17.50%. Notably, the stock represents an impressive one-year return of 100%.
Mesa Laboratories has a positive earnings surprise of 2.84% over the last four trailing quarters. Notably, the stock represents an impressive one-year return of 16.7%.
Edap Tms represents an impressive one-year return of 2.2% for the last three months. The company provided a solid earnings surprise of 533.3% in the last reported quarter.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation. See Them Free>>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Varian Halcyon System Gets 510(k) Approval from the FDA
Palo Alto, CA-based manufacturer of medical devices and software, Varian Medical Systems, Inc. recently announced the 510(k) approval for its Halcyon system. The Halcyon radiotherapy treatment system has been designed to offer cost-effective cancer care worldwide. In June Varian showcased the Halcyon system at the 2017 DEGRO meeting, the German radiation oncology society, in Berlin.
The Halcyon system streamlines every aspect of image-guided volumetric intensity modulated radiotherapy (IMRT). The system has received both 510(k) clearance and a CE mark from the European directive. Notably, Varian can initiate the selling process of the Halcyon system in the U.S. However, the system requires Eclipse 15.1.1 planning software, which is currently pending for a 510(k) approval.
Halcyon system has a user-friendly design and it automates, streamlines and simplifies almost every aspect of cancer treatment. Per management, the system offers treatment for prostate, breast, head & neck, and most other forms of cancer.
We note that the global radiotherapy market is expected to reach a worth of $7,544.8 million by 2020, at a CAGR of 6.2%. Taking the bountiful prospects in the global niche space into consideration, the latest development should boost investor confidence.
Price Movement
Varian has a Zacks Rank #2 (Buy).
The company has had an impressive run on the bourse over the last one month. Varian has gained almost 1.02%, higher than the Zacks classified Medical - Instruments sub-industry’s decline of 1.3%. Furthermore, the stock’s price level was higher than the S&P 500’s negative return of 0.6% over the same time frame.
Meanwhile, the company’s recent earnings estimates have been mixed at best. The current year has seen one analyst move north in the past two months, while next year estimates have seen two upward revisions, compared to no movement in the opposite direction.
This has had a significant impact on the consensus estimate, as the current quarter estimates lost roughly 1% over the last two months, while next year estimates increased 0.9%.
A few other top-ranked stocks in the broader medical sector are Inogen Inc. (INGN - Free Report) , Mesa Laboratories, Inc. (MLAB - Free Report) and Edap Tms S.a. (EDAP - Free Report) . Notably, all the stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Inogen has a long-term expected earnings growth rate of 17.50%. Notably, the stock represents an impressive one-year return of 100%.
Mesa Laboratories has a positive earnings surprise of 2.84% over the last four trailing quarters. Notably, the stock represents an impressive one-year return of 16.7%.
Edap Tms represents an impressive one-year return of 2.2% for the last three months. The company provided a solid earnings surprise of 533.3% in the last reported quarter.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation. See Them Free>>